These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 20801000)
1. Leishmaniasis vaccines: past, present and future. Modabber F Int J Antimicrob Agents; 2010 Nov; 36 Suppl 1():S58-61. PubMed ID: 20801000 [TBL] [Abstract][Full Text] [Related]
2. Vaccines for leishmaniasis in the fore coming 25 years. Palatnik-de-Sousa CB Vaccine; 2008 Mar; 26(14):1709-24. PubMed ID: 18295939 [TBL] [Abstract][Full Text] [Related]
3. Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis. Okwor I; Liu D; Uzonna J Vaccine; 2009 Apr; 27(19):2554-62. PubMed ID: 19428861 [TBL] [Abstract][Full Text] [Related]
9. Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems. Doroud D; Rafati S Expert Rev Vaccines; 2012 Jan; 11(1):69-86. PubMed ID: 22149710 [TBL] [Abstract][Full Text] [Related]
10. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721 [TBL] [Abstract][Full Text] [Related]
11. Progress towards a Leishmania vaccine. Tabbara KS Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009 [TBL] [Abstract][Full Text] [Related]
12. Leishmaniasis vaccine candidates for development: a global overview. Khamesipour A; Rafati S; Davoudi N; Maboudi F; Modabber F Indian J Med Res; 2006 Mar; 123(3):423-38. PubMed ID: 16778321 [TBL] [Abstract][Full Text] [Related]
13. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice. Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941 [TBL] [Abstract][Full Text] [Related]
17. The immunology of Leishmania infection and the implications for vaccine development. Vanloubbeeck Y; Jones DE Ann N Y Acad Sci; 2004 Oct; 1026():267-72. PubMed ID: 15604504 [TBL] [Abstract][Full Text] [Related]
18. Peptide Vaccines for Leishmaniasis. De Brito RCF; Cardoso JMO; Reis LES; Vieira JF; Mathias FAS; Roatt BM; Aguiar-Soares RDDO; Ruiz JC; Resende DM; Reis AB Front Immunol; 2018; 9():1043. PubMed ID: 29868006 [TBL] [Abstract][Full Text] [Related]
19. Genetically modified live attenuated parasites as vaccines for leishmaniasis. Selvapandiyan A; Duncan R; Debrabant A; Lee N; Sreenivas G; Salotra P; Nakhasi HL Indian J Med Res; 2006 Mar; 123(3):455-66. PubMed ID: 16778323 [TBL] [Abstract][Full Text] [Related]
20. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants. Poot J; Janssen LH; van Kasteren-Westerneng TJ; van der Heijden-Liefkens KH; Schijns VE; Heckeroth A Vaccine; 2009 Jul; 27(33):4439-46. PubMed ID: 19500553 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]